MetaCap

Tiziana Life Sciences (TLSA) vs Upstream Bio (UPB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tiziana Life Sciences (TLSA) has outperformed Upstream Bio (UPB) over the past year, losing 64.3% versus a loss of 93.8%. Upstream Bio is the larger company by market cap ($87.2 million vs $79.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TLSA-64.33%UPB-93.78%
+34%-33%-100%
Nov 21, 20251 yearNov 20, 2026
TLSA-33.98%UPB-92.77%
+165%+30%-105%
Oct 7, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TLSA versus UPB key metrics
MetricTLSAUPB
Share price$0.6206$1.59
Market cap$79.45M$87.15M
1-day change-8.14%-20.50%
YTD return-58.35%-94.14%
1-year return-64.33%-93.78%
5-year return-52.98%—
EPS (TTM)$-0.21$-3.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.85M
Revenue growth (YoY)—+20.42%
Net income (latest FY)$-11.86M$-143.44M
Operating margin—-5618.82%
Net margin—-5026.03%
52-week high$1.90$33.68
52-week low$0.55$1.56
Distance from 52-week high-67.34%-95.28%
Analyst consensusnonebuy
Avg. price target upside+1203.58%+1245.91%
Average volume606.04K1.01M
Shares outstanding128.03M54.81M
Employees1075
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TLSA has outperformed UPB by 29.4 percentage points over the past year.

About Tiziana Life Sciences

TLSA stock →

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About Upstream Bio

UPB stock →

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

TLSA vs UPB FAQ

Which is bigger, Tiziana Life Sciences or Upstream Bio?

Upstream Bio (UPB) is larger, with a market capitalization of $87.15M compared with $79.45M for Tiziana Life Sciences (TLSA).

Which stock has performed better over the past year, TLSA or UPB?

TLSA returned -64.33% over the past 12 months, compared with -93.78% for UPB (price return, excluding dividends). Past performance does not predict future results.

Are Tiziana Life Sciences and Upstream Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons